GlaxoSmithKline is investing in artificial ... where he was responsible for establishing new areas of research focus including the concepts of druggability and network pharmacology.

The inclusion of cancer in the new research partnership suggests GSK's continuing interest in the therapy area, despite its divestment of its marketed oncology portfolio to Novartis. Being first ...

International biotechnology company GlaxoSmithKline is moving its ... step to strengthen its presence in the Greater Boston area. The research and development teams will relocate from Rockville ...

In this article, we are going to take a look at where GSK plc (NYSE:GSK ... a wide range of companies that provide patient care, research and development of new medicines, and design, manufacture ...

Every year, amid Women’s History Month, March 8 marks International Women’s Day—a day dedicated to both honoring past efforts ...

UK drugmaker GSK is struggling to convince the market that ... particularly in speciality medicines and in areas like oncology.” The drugmaker does not have one potential mega blockbuster ...

Bernstein analyst Florent Cespedes maintained a Buy rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £22.90. The company’s shares opened today at p1,443. ...